Coronavirus disease 2019 (COVID-19) in neurology and neurosurgery: A scoping review of the early literature

MP Wilson, AS Jack - Clinical neurology and neurosurgery, 2020 - Elsevier
Coronavirus disease 2019 (COVID-19) is a devastating respiratory illness that has dramatically
changed the medical landscape around the world. In parallel with a rise in the number of …

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

…, F Offner, J Walewski, J Raposo, A Jack… - Blood, 2005 - ashpublications.org
The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several
standard treatment options for advanced follicular lymphoma. This, like similar …

[HTML][HTML] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a …

D Cunningham, EA Hawkes, A Jack, W Qian, P Smith… - The Lancet, 2013 - thelancet.com
Background Dose intensification with a combination of cyclophosphamide, doxorubicin,
vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than …

[HTML][HTML] Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

…, RG Owen, SJ Richards, AS Jack… - … England Journal of …, 2008 - Mass Medical Soc
Background A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over
5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer …

Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells

…, DM Meredith, AF Markham, A Jack… - Arthritis & …, 2002 - Wiley Online Library
Objective There is an increased interest in rheumatology in mesenchymal progenitor/stem
cells (MPCs) and their roles in rheumatic diseases, but little is known about the phenotype of …

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction …

…, RE Marcus, M Wolf, E Kimby, RD Gascoyne, A Jack… - Blood, 2006 - ashpublications.org
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment
of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were randomized to …

[PDF][PDF] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

…, R Owen, R Patmore, E Roman, A Jack - Journal of clinical …, 2010 - researchgate.net
Purpose Rearrangement of MYC occurs in a proportion of diffuse large B-cell lymphomas (DLBCL),
where they may be associated with an adverse clinical outcome. The aim of this …

Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

…, SJ Richards, GJ Morgan, AS Jack… - Blood, The Journal …, 2002 - ashpublications.org
Molecular and cellular markers associated with malignant disease are frequently identified
in healthy individuals. The relationship between these markers and clinical disease is not …

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

…, AP Haynes, GJ Morgan, AS Jack - Blood, The Journal …, 2002 - ashpublications.org
The International Prognostic Index (IPI) identifies poor- and good-risk patients with diffuse
large B cell lymphoma (DLBCL); however, the majority of patients have an intermediate IPI, …

Electrical stimulation as a tool to promote plasticity of the injured spinal cord

AS Jack, C Hurd, J Martin, K Fouad - Journal of Neurotrauma, 2020 - liebertpub.com
Jack … Material in this review was submitted in the thesis of Andrew S. Jack to fulfill the
requirements of a Master's in Neuroscience at the University of Alberta. …